Aducanumab Panel Pushes Back On Rosy FDA Outlook, Could Derail A Swift Approval
Executive Summary
An FDA advisory committee panel were critical of the agency’s review package for Biogen's aducanumab, raising uncertainty about the prospects of approval.
You may also be interested in...
Biogen Leans On Pipeline As Tecfidera, Spinraza See Q4 Sales Dip
The company sees aducanumab adding a modest boost to sales if approved, but there are another four Phase III programs with some major read-outs coming.
Aducanumab Approval Decision Delayed: Could This Be Good News?
Even analysts who still doubt the FDA will approve the anti-amyloid antibody as the first disease-modifying Alzheimer’s treatment said aducanumab’s likelihood of approval has improved.
The Top Five (Non-COVID) Pharma Stories Of 2020
The (virtual) doors closing on the J.P. Morgan Healthcare Conference is the sign for the biopharma industry that the new year has truly started, but before we get too far into 2021, Scrip has taken a look at five of the biggest non-COVID-19 story themes of 2020 in no particular order.
Need a specific report? 1000+ reports available
Buy Reports